Abstract Recurrent GBM (rGBM) is the most aggressive malignant brain tumors, with a median survival of 6 months. rGBM establishes a severe immunosuppressive tumor microenvironment (TME) with increased Tregs and impaired CD8 T cell recruitment, rendering immunotherapies effective in other cancers ineffective. While IL-12 is a potent immunostimulatory cytokine capable of remodeling this immunosuppressive TME, systemic delivery causes severe toxicity, hindering clinical application. Therefore, technology to selectively deliver IL-12 to rGBM tumors is critically needed. rGBM acquires treatment resistance through construction of a unique extracellular matrix (ECM); therefore, we conceived of utilizing this as a reservoir to accumulate IL-12. Through screening, we focused on COL I Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7783.
Iwaloye et al. (Fri,) studied this question.